Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BGT226||NVP-BGT226||mTOR Inhibitor 51 PI3K Inhibitor (Pan) 38||BGT226 is a dual inhibitor of class I PI3K kinases and mTOR, which may inhibit tumor celll proliferation and tumor growth (PMID: 21976531, PMID: 31190275).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||BGT226||Phase I||Actionable||In a Phase I trial of BGT226 in patients with advanced solid tumors, limited preliminary antitumor activity and inconsistent target inhibition were observed (PMID: 22357447).||22357447|
|Unknown unknown||Advanced Solid Tumor||not applicable||BGT226||Phase I||Actionable||In a Phase I trial, BGT226 treatment was tolerated, and resulted in stable disease as best response in 28% (5/18) of patients with advanced solid tumors (PMID: 31192075).||31192075|
|Unknown unknown||T-cell acute lymphoblastic leukemia||not applicable||BGT226||Preclinical - Cell culture||Actionable||In a preclinical study, BGT226 treatment inhibited viability of NUP214-ABL1 fusion-positive T-cell acute lymphoblastic leukemia cell lines in culture (PMID: 27821800).||27821800|
|PTEN loss||acute lymphoblastic leukemia||sensitive||BGT226||Preclinical - Cell culture||Actionable||In a preclinical study, BGT226 treatment in PTEN-deficient acute lymphoblastic leukemia cells resulted in inhibition of PI3K/Akt signaling and apoptotic activity in culture (PMID: 23705826).||23705826|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|